Drug Information Analysis Service

Carter BL Jones ME Waickman LA . Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism. Clin Pharm 1985; 4: 279–96.

Richens A . Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979; 4: 153–89.

Peterson LR Gerding DN . Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: Clinically useful concepts. Rev Infect Dis 1980; 2: 340–8.

Craig WA Kunin CM . Significance of serum protein and tissue binding of antimicrobial agents. Ann Rev Med 1976; 27: 287–300.

Wise R . Protein binding of B-lactams; the effects on activity and pharmacology, particularly penetration. J Antimicrob Chemother 1983; 12: 1–16.

Cherubin CE Eng R Appleman X . A critique of semiautomated susceptibility systems. Rev Infect Dis 1987; 9: 655–9.

Shaw PM Jaewisch E . Activity of third-generation cephalosporins in human blood. Clin Ther 1983; 6: 72–8.

Jones RN Barry AL . Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime desacetylcefotaxime in the presence of human serum. Antimicrob Agents Chemother 1987; 31: 818–20.

Schumaker GE . Comparison of antibiotic dosage regimens using pharmacokinetic and microbiologic factors. Clin Pharm 1987; 6: 59–68.

Wise R . The clinical significance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986; 11: 470–82.

Product information. Claforan (cefotaxime sodium). Somerville, NJ: Hoechst-Roussel, April 1986.

Product information. Cefobid (cefoperazone sodium). New York: Roerig, 1987.

Drusano GL Ryan PA . Integration of selected pharmacologic and microbiologic properties of three new B-lactam antibiotics: A hypothesis for rational comparison. Rev Infect Dis 1984; 6: 357–63.

Drusano GL . Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32; 289–97.

Sanford JP . Guide to antimicrobial therapy 1987. 16th ed. San Antonio, TX: Antimicrobial Therapy, 1987: 48.

Dudley MN Shyu WC Nightingale CH Quintiliani R . Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. Antimicrob Agents Chemother 1986; 30: 565–9.

Wise R . Protein binding of β-lactams: The effects of activity and pharmacology, particularly tissue penetration. II. J Antimicrob Chemother 1983; 12: 105–18.

Thomas CL , ed. Taber's cyclopedic medical dictionary. Philadelphia: FA Davis Company, 1977: x–2.

Speilman A Ben-Aryeh H Gutman D Szargel R Duetsche E . Xerostomia—diagnosis and treatment. Oral Surg 1981; 51: 144–7.

Fox PC Van Der Ven PF Sonies BC Weiffenbach JM Baum BJ . Xerostomia: Evaluation of a symptom with increasing significance. JADA 1985; 110: 519–25.

Glass BJ Van Dis ML Langlais RP Miles DA . Xerostomia: Diagnosis and treatment planning considerations. Oral Surg 1984; 58: 248–52.

Bahn SL . Drug-related dental destruction. Oral Surg 1972; 33: 49–54.

Dreizen S Brown LR Handler S Levy BM . Radiation-induced xerostomia in cancer patients. Cancer 1976; 38: 273–8.

Shannon IL McCrary BR Starcke EN . A saliva substitute for use by xerostomic patients undergoing radiotherapy to the head and neck. Oral Surg 1977; 44: 656–61.

Greenspan D Daniels TE . Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987; 59: 1123–5.

Gegick CG Levitin PM . Relief of xerostomia in Sjögren's syndrome. South Med J 1977; 70: 1131.

Fann WE Shannon IL . A treatment for dry mouth in psychiatric patients. Am J Psych 1978; 135: 251–2.

Tyler VE Brady LR Robbers JE , eds. Pharmacognosy. Philadelphia: Lea & Febiger, 1981: 249.

Palmer T . Cholinergic agonists. In: Gilman AG Goodman LS Rall TW Murad F , eds. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 105–8.

Dawes C . The composition of human saliva secreted in response to a gustatory stimulus and to pilocarpine. J Physiol 1966; 183: 360–8.

Rifkin A . Drug induced exacerbations of porphyria. Prim Care 1976; 3: 665–85.

Khanderia MS Bhattacharya A . Acute intermittent porphyria: Pathophysiology and treatment. Pharmacol Ther 1984; 4: 144–50.

Goldberg A . Acute intermittent porphyria: A study of 50 cases. Q J Med 1959; 28: 183–209.

Moore MR . International review of drugs in acute porphyria. Int J Biochem 1980; 12: 1089–97.

Morse RH . Porphyria and pain management. Chronic Pain Rev 1984; 136: 15–8.

Disler PB Blekkenhorst GH Eales L Moore MR Straughan J . Guidelines for drug prescription in patients with acute porphyria. South Afr Med J 1982; 61: 656–60.

Eales L . Acute porphyria: The precipitating and aggravating factors. South Afr J Lab Clin Med 1971; 17: 120–2.

Eales L . Porphyria and the dangerous life-threatening drugs. South Afr J Clin Med 1979; 56: 914–7.

Moore MR McColl KE Goldberg A . The porphyrias. Diabetes Metab 1979; 5: 323–36.

Badaway AA . Treatment of acute hepatic porphyria. Lancet 1978; 1: 1361–2.